potentially involved in the problematic and practitioners to understand and use of these pharmaceuticals. be more involved in managing pain). 7.6 Explore opportunities to expand Pillar 3: Harm reduction, NSPs into rural areas to a larger extent Objective 3 (Reduce harms to than is currently the case. individuals). 8.1 Promote the use of tamper-resistant Pillar 2: Supply Reduction, Objective 3: Gain the technologies for target medications. Objective 2 (Control and Manage commitment of the the supply of alcohol, tobacco medicines industry to the and other legal drugs). quality use of medicines. 8.2 Consider the feasibility of Pillar 2: Supply Reduction, Objective 3: Gain the Goal 5: Quality improvement and implementing pharmaceutical Objective 2 (Control and Manage commitment of the evaluation, Objective 5 (Ensure pedigrees. the supply of alcohol, tobacco medicines industry to the quality use of medicines for pain and other legal drugs). quality use of medicines. management and improve systems to detect and manage unsanctioned use. 8.3 Enhance the use of electronic Pillar 2: Supply Reduction, Goal 5: Quality improvement and prescriptions to minimise the risk of Objective 2 (Control and Manage evaluation, Objective 5 (Ensure dispensing errors and fraudulent the supply of alcohol, tobacco quality use of medicines for pain alteration of prescriptions. and other legal drugs). management and improve systems to detect and manage unsanctioned use. 9.1 Enhance and better co-ordinate Supporting approaches 2: Goal 6: Research, Objective 22 Policy direction 10: (Building and pharmaceutical-related data collection (Commitment to evidence). (Enable pain research at a national the evidence base). and sharing processes to provide a Objective 23 (Identify more holistic picture of patterns of the information gaps underpinning all prescription and utilisation as well as objectives in the NPS) and Objective 24 (Ensure research is relevant to profiles and levels of harm. populations with special needs). 9.2 Conduct a range of specific Supporting approaches 2: Goal 6: Research, Objective 22 Policy direction 10: (Building and research activities to focus on areas (Commitment to evidence). (Enable pain research at a national using the evidence base). that could better inform public policy in level), Objective 23: (Identify this area. information gaps underpinning all objectives in the NPS) and Objective
potentially involved in the problematic use of these pharmaceuticals. and practitioners to understand and be more involved in managing pain). 7.6 Explore opportunities to expand NSPs into rural areas to a larger extent than is currently the case. Pillar 3: Harm reduction, Objective 3 (Reduce harms to individuals). 8.1 Promote the use of tamper-resistant technologies for target medications. Pillar 2: Supply Reduction, Objective 2 (Control and Manage the supply of alcohol, tobacco and other legal drugs). Objective 3: Gain the commitment of the medicines industry to the quality use of medicines. 8.2 Consider the feasibility of implementing pharmaceutical pedigrees. Pillar 2: Supply Reduction, Objective 2 (Control and Manage the supply of alcohol, tobacco and other legal drugs). Objective 3: Gain the commitment of the medicines industry to the quality use of medicines. Goal 5: Quality improvement and evaluation, Objective 5 (Ensure quality use of medicines for pain management and improve systems to detect and manage unsanctioned use. 8.3 Enhance the use of electronic prescriptions to minimise the risk of dispensing errors and fraudulent alteration of prescriptions. Pillar 2: Supply Reduction, Objective 2 (Control and Manage the supply of alcohol, tobacco and other legal drugs). Goal 5: Quality improvement and evaluation, Objective 5 (Ensure quality use of medicines for pain management and improve systems to detect and manage unsanctioned use. 9.1 Enhance and better co-ordinate pharmaceutical-related data collection and sharing processes to provide a more holistic picture of patterns of the prescription and utilisation as well as profiles and levels of harm. Supporting approaches 2: (Commitment to evidence). Goal 6: Research, Objective 22 (Enable pain research at a national Objective 23 (Identify information gaps underpinning all objectives in the NPS) and Objective 24 (Ensure research is relevant to populations with special needs). Policy direction 10: (Building and the evidence base). 9.2 Conduct a range of specific research activities to focus on areas that could better inform public policy in this area. Supporting approaches 2: (Commitment to evidence). Goal 6: Research, Objective 22 (Enable pain research at a national level), Objective 23: (Identify information gaps underpinning all objectives in the NPS) and Objective Policy direction 10: (Building and using the evidence base).